药品注册申请号:020597
申请类型:NDA (新药申请)
申请人:UPJOHN
申请人全名:UPJOHN US 2 LLC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 XALATAN LATANOPROST SOLUTION/DROPS;OPHTHALMIC 0.005% Yes Yes AT 1996/06/05 1996/06/05 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2022/12/19 SUPPL-54(补充) Approval Labeling STANDARD
2020/09/01 SUPPL-52(补充) Approval Labeling STANDARD
2017/04/10 SUPPL-51(补充) Approval Labeling STANDARD
2014/11/25 SUPPL-48(补充) Approval Labeling STANDARD
2014/11/25 SUPPL-45(补充) Approval Labeling STANDARD
2014/04/03 SUPPL-49(补充) Approval Manufacturing (CMC) PRIORITY
2013/03/13 SUPPL-46(补充) Approval Manufacturing (CMC) PRIORITY
2012/03/13 SUPPL-44(补充) Approval Labeling STANDARD
2010/08/31 SUPPL-36(补充) Approval Labeling STANDARD
2010/08/31 SUPPL-35(补充) Approval Labeling STANDARD
2010/07/29 SUPPL-39(补充) Approval Manufacturing (CMC) N/A
2003/07/14 SUPPL-29(补充) Approval Manufacturing (CMC) PRIORITY
2003/07/14 SUPPL-28(补充) Approval Labeling STANDARD
2002/12/20 SUPPL-10(补充) Approval Efficacy PRIORITY
2002/11/15 SUPPL-26(补充) Approval Manufacturing (CMC) PRIORITY
2002/08/26 SUPPL-25(补充) Approval Manufacturing (CMC) PRIORITY
2002/06/21 SUPPL-24(补充) Approval Manufacturing (CMC) PRIORITY
2001/11/26 SUPPL-23(补充) Approval Manufacturing (CMC) PRIORITY
2001/08/08 SUPPL-19(补充) Approval Labeling STANDARD
2001/05/14 SUPPL-22(补充) Approval Manufacturing (CMC) PRIORITY
2001/04/23 SUPPL-20(补充) Approval Manufacturing (CMC) PRIORITY
2000/12/26 SUPPL-14(补充) Approval Labeling STANDARD
2000/12/11 SUPPL-17(补充) Approval Manufacturing (CMC) PRIORITY
2000/11/09 SUPPL-16(补充) Approval Manufacturing (CMC) PRIORITY
2000/08/25 SUPPL-18(补充) Approval Labeling STANDARD
2000/06/02 SUPPL-13(补充) Approval Manufacturing (CMC) PRIORITY
2000/01/24 SUPPL-11(补充) Approval Manufacturing (CMC) PRIORITY
1999/10/08 SUPPL-12(补充) Approval Labeling STANDARD
1999/07/16 SUPPL-8(补充) Approval Labeling STANDARD
1999/03/22 SUPPL-7(补充) Approval Labeling STANDARD
1998/12/09 SUPPL-2(补充) Approval Manufacturing (CMC) PRIORITY
1998/11/01 SUPPL-6(补充) Approval Manufacturing (CMC) PRIORITY
1998/07/31 SUPPL-5(补充) Approval Manufacturing (CMC) PRIORITY
1998/06/23 SUPPL-1(补充) Approval Labeling STANDARD
1996/06/05 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 4599353 2006/07/28 U-260 PDF格式**本条是由Drugfuture回溯的历史信息**
5296504 2011/03/22 Y U-778 PDF格式**本条是由Drugfuture回溯的历史信息**
5422368 2011/03/22 Y U-778 PDF格式**本条是由Drugfuture回溯的历史信息**
6429226 2009/09/06 Y U-778 PDF格式**本条是由Drugfuture回溯的历史信息**
7163959 2010/06/19 Y PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:LATANOPROST 剂型/给药途径:SOLUTION/DROPS;OPHTHALMIC 规格:0.005% 治疗等效代码:AT
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
020597 001 NDA XALATAN LATANOPROST SOLUTION/DROPS;OPHTHALMIC 0.005% Prescription Yes Yes AT 1996/06/05 UPJOHN
091449 001 ANDA LATANOPROST LATANOPROST SOLUTION/DROPS;OPHTHALMIC 0.005% Prescription No No AT 2011/03/22 SANDOZ
200925 001 ANDA LATANOPROST LATANOPROST SOLUTION/DROPS;OPHTHALMIC 0.005% Prescription No No AT 2011/03/22 AMRING PHARMS
201006 001 ANDA LATANOPROST LATANOPROST SOLUTION/DROPS;OPHTHALMIC 0.005% Prescription No No AT 2011/03/22 BAUSCH AND LOMB
201786 001 ANDA LATANOPROST LATANOPROST SOLUTION/DROPS;OPHTHALMIC 0.005% Prescription No No AT 2011/03/22 SOMERSET
090887 001 ANDA LATANOPROST LATANOPROST SOLUTION/DROPS;OPHTHALMIC 0.005% Discontinued No No AT 2011/07/19 EPIC PHARMA LLC
202077 001 ANDA LATANOPROST LATANOPROST SOLUTION/DROPS;OPHTHALMIC 0.005% Prescription No No AT 2013/02/11 RYAN LABS
202442 001 ANDA LATANOPROST LATANOPROST SOLUTION/DROPS;OPHTHALMIC 0.005% Prescription No No AT 2016/04/22 FDC LTD
218257 001 ANDA LATANOPROST LATANOPROST SOLUTION/DROPS;OPHTHALMIC 0.005% Prescription No No AT 2024/11/26 GLAND
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database